← Leaderboards
Ahmed Kaseb
University Of Tx Md Anderson Can Ctr
$3,699,074
Attributed
$5,685,897
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,955,901 · 6
By mechanism
P50$13,227,222 · 3
R01$2,980,235 · 1
R21$748,444 · 2
Top collaborators
- Hesham M Amin5 shared
- Laura Beretta5 shared
- Dan Gabriel Duda5 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Cielito C Reyes-Gibby$3,873,330
- Tina Cascone$2,250,345
- Hesham M Amin$3,011,396
- David Fuentes$1,768,670
- Eugene J Koay$2,020,718
Others in their field
Top investigators on “Primary Carcinoma Of The Liver Cells”
- David Heimbrook · Leidos Biomedical Research, Inc.$56,561,099
- Charles M. Rice · Rockefeller University$25,448,599
- Michael Karin · University Of California, San Diego$20,421,657
- Amit Singal · Ut Southwestern Medical Center$15,537,004
- Raymond T Chung · Massachusetts General Hospital$13,602,946
- Dean W Felsher · Stanford University$13,140,261
Research focus
Primary Carcinoma Of The Liver CellsPharmaceutical PreparationsInnovationBay 54-9085ResponseExcisionOperative Surgical ProceduresTumorResectedCellsMortalityNeoadjuvant TherapyRecurrenceImmune CheckpointImmuneImmunotherapyNivolumabResectableClinical TrialsPlasmaProgrammed Cell Death Ligand 1BaseAdverse EventBiological Markers
Grant awards (19)
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients$461,706
R01 · FY2025 · CA · contact PI
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients$590,031
R01 · FY2024 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma$2,206,679
P50 · FY2023 · CA
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients$608,666
R01 · FY2023 · CA · contact PI
Project 1: Targeting the PD-1 pathway in HCC$376,652
P50 · FY2023 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma$2,278,344
P50 · FY2022 · CA
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients$608,661
R01 · FY2022 · CA · contact PI
Project 1: Targeting the PD-1 pathway in HCC$376,651
P50 · FY2022 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma$2,156,230
P50 · FY2021 · CA
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients$711,171
R01 · FY2021 · CA · contact PI
Project 1: Targeting the PD-1 pathway in HCC$439,497
P50 · FY2021 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma$2,332,104
P50 · FY2020 · CA
Project 1: Targeting the PD-1 pathway in HCC$387,766
P50 · FY2020 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma$2,296,647
P50 · FY2019 · CA
Project 1: Targeting the PD-1 pathway in HCC$376,652
P50 · FY2019 · CA · contact PI
Novel Point-of-Care Tool to Predict Response to Sorafenib in Hepatocellular Carcinoma$208,800
R21 · FY2017 · CA · contact PI
Novel Point-of-Care Tool to Predict Response to Sorafenib in Hepatocellular Carcinoma$174,000
R21 · FY2016 · CA · contact PI
Integrating plasma IGF-1 into novel classification of hepatocellular carcinoma$193,819
R21 · FY2013 · CA · contact PI
Integrating plasma IGF-1 into novel classification of hepatocellular carcinoma$171,825
R21 · FY2012 · CA · contact PI